Larry Mathis Financial Planning LLC Acquires Shares of 4,834 Gilead Sciences, Inc. $GILD

Larry Mathis Financial Planning LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 4,834 shares of the biopharmaceutical company’s stock, valued at approximately $593,000.

Several other large investors have also made changes to their positions in GILD. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences during the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC boosted its position in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares in the last quarter. Quattro Advisors LLC acquired a new position in Gilead Sciences in the fourth quarter valued at about $26,000. Wealth Preservation Advisors LLC grew its stake in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in Gilead Sciences during the fourth quarter worth about $28,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the transaction, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. This trade represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 68,000 shares of company stock valued at $8,930,150 over the last 90 days. 0.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

GILD has been the subject of a number of research analyst reports. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research note on Wednesday, May 20th. Jefferies Financial Group initiated coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price target on the stock. Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Morgan Stanley cut their price objective on Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research report on Tuesday. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $158.41.

Gilead Sciences Price Performance

Shares of GILD stock opened at $123.76 on Friday. Gilead Sciences, Inc. has a 1 year low of $104.46 and a 1 year high of $157.29. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. The firm’s 50 day moving average is $131.66 and its 200-day moving average is $134.21. The firm has a market capitalization of $153.66 billion, a price-to-earnings ratio of 16.86 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. During the same quarter last year, the business posted $1.81 earnings per share. Gilead Sciences’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post -0.8 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences’s payout ratio is presently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.